A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects

NCT07065058 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity &Amp; Overweight

Interventions

DRUG: Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin

Sponsor

Vincentage Pharma Co., Ltd